A shift towards neoadjuvant therapy in resectable pancreatic adenocarcinoma may enhance surgical success rates. This approach addresses micro-metastatic disease present in many patients, highlighting the necessity of systemic therapy irrespective of resectability. It further allows for tailored treatment selections based on individual tumor biology. Evidence supporting the adoption of neoadjuvant treatment is growing, indicating better tolerability and improved outcomes compared to traditional postoperative interventions.
Review by Johnson R, McClelland PH and Ahmad SA in Surg Clin North Am
Copyright © 2024 Elsevier Inc. All rights reserved.